In a filing, Acadia Pharmaceuticals Inc revealed its PRINCIPAL ACCOUNTING OFFICER Kihara James unloaded Company’s shares for reported $19374.0 on May 02 ’25. In the deal valued at $14.60 per share,1,327 shares were sold. As a result of this transaction, Kihara James now holds 23,526 shares worth roughly $0.41 million.
Then, Schneyer Mark C. sold 3,498 shares, generating $51,071 in total proceeds. Upon selling the shares at $14.60, the EVP, CHIEF FINANCIAL OFFICER now owns 62,773 shares.
Before that, Schneyer Mark C. sold 2,708 shares. Acadia Pharmaceuticals Inc shares valued at $40,133 were divested by the EVP, CHIEF FINANCIAL OFFICER at a price of $14.82 per share. As a result of the transaction, Schneyer Mark C. now holds 59,456 shares, worth roughly $1.04 million.
Deutsche Bank initiated its Acadia Pharmaceuticals Inc [ACAD] rating to a Hold in a research note published on February 11, 2025; the price target was $22. A number of analysts have revised their coverage, including Guggenheim’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Morgan Stanley revised its rating on August 07, 2024. It rated ACAD as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of ACAD
On Friday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock jump 3.01% to $17.44. Over the last five days, the stock has gained 16.97%. Acadia Pharmaceuticals Inc shares have fallen nearly -4.96% since the year began. Nevertheless, the stocks have risen 1.10% over the past one year. While a 52-week high of $20.68 was reached on 02/21/25, a 52-week low of $13.40 was recorded on 04/09/25. SMA at 50 days reached $16.07, while 200 days put it at $16.67.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 16.92, which if violated will result in even more drops to 16.41. On the upside, there is a resistance level at 17.79. A further resistance level may holdings at 18.14. The Relative Strength Index (RSI) on the 14-day chart is 67.70, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.35, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 5.08%. Stochastics %K at 81.68% indicates the stock is a selling.
The most recent change occurred on June 27, 2024 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
